LianBio
Close on Oct 19, 2026
- Market cap
- $6.29M
- P/E (TTM)
- –
- Dividend yield
- –
About LianBio
Pharmaceutical Preparations, SIC 2834
LianBio is a clinical-stage biopharmaceutical company focused on bringing innovative therapies to patients with unmet medical needs across Asia, primarily targeting Greater China and other regional markets. The company operates by in-licensing differentiated therapeutic assets that have established clinical proof of concept from global partners. Its pipeline includes eight therapeutic candidates across four core disease indications: cardiovascular conditions, oncology, ophthalmology, and inflammatory diseases. Key programs undergoing clinical development include mavacamten for obstructive hypertrophic cardiomyopathy, TP-03 for Demodex blepharitis, and NBTXR3 for head and neck cancers. LianBio develops these treatments to serve patients requiring novel medical interventions.
The company maintains operational activities across mainland China, the Asia Pacific region, and the United States. Research and development operations are based in Shanghai, China, while primary executive offices are located in Princeton, New Jersey, and its corporate registered office is situated in George Town, Grand Cayman.
Summary of the business section of LianBio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LianBio
- Founded
- 2019
- Headquarters
- Princeton, NJ
- Address
- 103 Carnegie Center Drive, Suite 309 08540
- Phone
- (609) 486-2308
- Website
- lianbio.com
- Employees
- 163, Dec 31, 2022
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, New York
Stock & identifiers
- Ticker
- LIANY
- Exchange
- OTC
- IPO date
- Nov 2, 2021
- Shares outstanding
- 108M, Nov 9, 2023
- Public float
- $97.30M, Jun 30, 2022
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1831283
- CUSIP
- 53000N108
- ISIN
- US53000N1081
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
LianBio's leadership is listed in its proxy statement, last filed Apr 19, 2023.
Employees
Headcount reported in annual reports
“As of December 31, 2022, we had 163 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 21, 2024 | Deregistration | Termination of SEC registration (Form 15) |
| Mar 11, 2024 | Delisting | Notice of delisting from exchange (Form 25) |
| Feb 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 30, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 2, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 20, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |